Welcome to our dedicated page for 89bio news (Ticker: $ETNB), a resource for investors and traders seeking the latest updates and insights on 89bio stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect 89bio's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of 89bio's position in the market.
Rhea-AI Summary
89bio, Inc. (ETNB) Announces Approval of Non-Qualified Stock Options for New Employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.71%
Tags
-
Rhea-AI Summary
89bio, Inc. (ETNB) successfully closed an upsized underwritten public offering, raising approximately $172.5 million. The company sold 17,567,567 shares of its common stock and pre-funded warrants to purchase up to 1,081,081 shares. The offering was led by BofA Securities and Leerink Partners, with H.C. Wainwright & Co. as the lead manager. The gross proceeds will be used for the development and commercialization of innovative therapies for liver and cardiometabolic diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.27%
Tags
-
Rhea-AI Summary
89bio, Inc. (ETNB) announces the pricing of an upsized underwritten public offering of 15,135,135 shares of its common stock at a public offering price per share of $9.25, with expected gross proceeds of approximately $150.0 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.1%
Tags
News
Rhea-AI Summary
89bio, Inc. (ETNB) has announced a public offering of $125.0 million of its common stock or pre-funded warrants. The company aims to use the proceeds for clinical activities, development of pegozafermin, manufacturing scale-up, and general corporate purposes. The offering is subject to market conditions and will be managed by BofA Securities, Leerink Partners, Cantor, Raymond James, UBS Investment Bank, and H.C. Wainwright & Co.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.1%
Tags
-
Rhea-AI Summary
89bio, Inc. (ETNB) successfully concluded an end-of-Phase 2 Meeting with the FDA, supporting the advancement of pegozafermin into Phase 3 in NASH. The program will include two Phase 3 trials evaluating patients with NASH: ENLIGHTEN-Cirrhosis for F4 patients and ENLIGHTEN-Fibrosis for F2-F3 patients. The FDA has agreed to an accelerated approval pathway for both F4 and F2-F3 NASH patients using histology. The safety database will include data from the ongoing SHTG Phase 3 program. The trials will include patients on background GLP-1 therapy to assess the potential combination with pegozafermin. The ENLIGHTEN program will evaluate the efficacy and safety of pegozafermin in patients with NASH, with the trials expected to initiate in the first and second quarter of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.74%
Tags
-
Rhea-AI Summary
89bio, a clinical-stage biopharmaceutical company (ETNB) focused on liver and cardiometabolic disease therapies, announced positive Phase 2b ENLIVEN trial data for pegozafermin in NASH patients. The 48-week treatment demonstrated sustained improvements in liver health markers, including liver fat, inflammation, and fibrosis, with favorable safety profile.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.66%
Tags
Rhea-AI Summary
89bio, Inc. (ETNB) to participate in fireside chat at Evercore HEALTHCONx Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.13%
Tags
-
Rhea-AI Summary
89bio, Inc. (Nasdaq: ETNB) announces new data from ENLIVEN Phase 2b trial on pegozafermin treatment for F4 NASH patients. Results show improvements in liver specific biomarkers, fibrosis, and inflammation, with a responder analysis suggesting a correlation between NIT-based improvements and histological measures. Safety profile remains favorable. The company plans to initiate Phase 3 program in the first half of next year pending regulatory feedback.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
89bio, Inc. (ETNB) has been granted Breakthrough Therapy Designation (BTD) for pegozafermin in treating NASH with fibrosis. The company expects regulatory feedback on its Phase 3 development program this quarter. Data from ENLIVEN in patients with cirrhotic (F4) NASH will be presented at AASLD. Financial results for Q3 2023 show $448.3 million in cash and a net loss of $34.7 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.86%
Tags
Rhea-AI Summary
89bio to participate in H.C. Wainwright NASH Investor Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.41%
Tags
89bio, Inc.
Nasdaq:ETNB
ETNB Rankings
ETNB Stock Data
913.21M
69.50M
0.86%
106.21%
12.35%
Pharmaceutical Preparation Manufacturing
Manufacturing
United States of America
SAN FRANCISCO
About ETNB
89bio, inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. its lead product candidate is bio89-100, a glycopegylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. the company also intends to develop bio89-100 for the treatment of severe hypertriglyceridemia. 89bio, inc. was founded in 2018 and is based in san francisco, california.